The Liston-Dooley laboratory is based within the Department of Pathology of the University of Cambridge. The Liston-Dooley lab aims to understand the interaction of the immune system and the tissues during pathology, and to harness this understanding for therapeutic benefit. In particular, we are currently focused on regulatory T cells in the tissues, and the potential these anti-inflammatory cells have to control pathology during injury, autoimmunity and infection, in key sites such as the brain and lung. The laboratory has extensive experience in mouse immunology, clinical immunology, immunogenetics, neuroimmunology, systems immunology, disease models, high-dimensional flow cytometry, and vector engineering.
The Liston-Dooley lab started in 2009, when Prof Adrian Liston and Dr James Dooley developed an independent research labratory at the University of Leuven Department of Microbiology and Immunology and the VIB Center for Brain and Disease Research. The laboratory successfully ran a translational and clinicial immunology program for 10 years, in addition to starting up core facilities in flow cytometry and genome engineering, before moving the lab to the Babraham Institute. Between 2019 and 2023, the Liston-Dooley lab worked on biotechnology developments in neuroinflammation, developing new therapeutic approaches and setting up a spin-off company Aila Biotech Ltd. In 2023, the Liston-Dooley laboratory relocated to the Department of Pathology, where Liston took up the position of Professor of Pathology.
Previous research topics in the laboratory are now continued in the independent labs of alumni Prof Susan Schlenner, Prof Stephanie Humblet-Baron, Prof Lidia Yshii, Prof Kailash Singh, and Prof Emanuela Pasciuto, through programs that are now core facilities, FACS Core and MutaMouse, and through the spin-off company Aila Biotech.
Listen to an interview with Adrian on Nature Podcast here to learn more about the lab.
